Muscle Cramps
Also known as: Charley horse, Thighs, Femurs, Femoral
Methodology & AI Transparency ⓘ
Muscle Cramps Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are muscle cramps? Muscle cramps are sudden, involuntary contractions or spasms in one or more of your muscles.
- 2 Real-world patient consensus: Mapped to Chronic Kidney Disease & Electrolytes under ICD-10-CM R25.2 for Muscle Cramps clinical workups.
- 3 Typical cash cost range: Workup highlights for Muscle Cramps (R25.2): NSAID/nephrotoxin avoidance [Muscle Cramps R25.2].
- 4 Top reported side effects / signs: Follow-up benchmark in Muscle Cramps: maintaining Serum Potassium, Bicarbonate in Muscle Cramps (R25.2: & Phosphorus) within K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (R25.2).
Ask our AI Specialists anything about Muscle Cramps
What Is Muscle Cramps?
What are muscle cramps? Muscle cramps are sudden, involuntary contractions or spasms in one or more of your muscles. They are very common and often occur after exercise. Some people get muscle cramps, especially leg cramps, at night. They can be painful, and they may last a few seconds to several minutes. You can have a cramp in any muscle, but they happen most often in the: Thighs Feet Hands Arms Abdomen Area along your ribcage What causes muscle cramps? Causes of muscle cramps include: Straining or overusing a muscle. This is the most common cause.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Muscle Cramps (code R25.2) is intrarenal RAAS activation [Muscle Cramps R25.2], Cross-referenced with NIH MeSH (Muscle Cramp), which Chronic Kidney Disease & Electrolytes clinicians address while surveilling Serum Potassium, Bicarbonate in Muscle Cramps (R25.2: & Phosphorus) (K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (R25.2)).
Common Symptoms & Clinical Signs
- • Area along your ribcage
- • Straining or overusing a muscle. This is the most common cause
- • Presentation of Muscle Cramps (R25.2): fatigue, muscle cramps, in Muscle Cramps (R25.2: metallic taste, or)
- • Secondary Muscle Cramps clinical sign: changes in urine in Muscle Cramps (R25.2: output volume, nocturnal)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Muscle Cramps Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R25.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Muscle Cramps (R25.2: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (R25.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Muscle Cramps (R25.2: Cystatin C)) | >= 90 mL/min/1.73m2 (R25.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Muscle Cramps (R25.2: (uACR)) | < 15 mg/g (< 30 mg/g normal) (R25.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Muscle Cramps
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Atmeksi (Methocarbamol) Atmeksi • RxCUI 197943-B69528701 | Muscle Relaxant | 92% | $8.3480 | $ 609.56 /mo |
| Soma (Carisoprodol) Soma • RxCUI RXN-B00372001 | Muscle Relaxant | 93% | $11.2975 | $ 640.00 /mo |
| Muscle Rub Cream (Menthol 10%, Methyl Salicylate 15%) Muscle Rub Cream • RxCUI 311498-B69396110 | Over-the-Counter Clinical Monograph | 91% | $0.8804 | $ 71.89 /mo |
| Atracurium Besylate Atracurium Besylate Generic • RxCUI 966768 | Nondepolarizing Neuromuscular Blocker | 88% | $1.3200 | $ 61.96 /mo |
| Cyclobenzaprine Hydrochloride Fexmid, Amrix • RxCUI 828320 | Muscle Relaxant | 94% | $0.0169 | $ 5.36 /mo |
| Fexmid (Cyclobenzaprine Hydrochloride) Fexmid • RxCUI 828299 | Muscle Relaxant | 89% | $0.2402 | $ 25.80 /mo |
| Amrix (Cyclobenzaprine Hydrochloride) Amrix • RxCUI 828353 | Muscle Relaxant | 92% | $66.2326 | $ 24.77 /mo |
| Lidocaine and Camphor Olu Pain Management • RxCUI 2700664 | Amide Local Anesthetic | 85% | $0.0989 | $ 12.50 /mo |
| Tanlor (Methocarbamol) Tanlor • RxCUI 2611794 | Muscle Relaxant | 76% | $8.3480 | $ 609.56 /mo |
| Elamipretide Hydrochloride Forzinity • RxCUI 2725604 | FDA Prescription Therapeutic Agent | 76% | $0.5400 | $ 30.37 /mo |
| Cyclobenzaprine HCl ER Cyclobenzaprine HCl ER Generic • RxCUI RXN-72189389-2594 | Muscle Relaxant | 81% | $0.0177 | $ 9.22 /mo |
| Vecuronium Bromide Vecuronium Bromide Generic • RxCUI 859437 | Nondepolarizing Neuromuscular Blocker | 93% | $2.9200 | $ 126.76 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Muscle Cramps)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Real-world benefits and safety of NVP-1203 and aceclofenac in patients with acute: What a 455-Participant Study Found NVP-1203 is more effective in reducing pain than the 100 mg aceclofenac alone. European review for medical and pharmacological sciences • 2023-01-15 • Phase III Randomized Trial | N = 455 | 93/100 | PMID 36647880 ↗ |
| New Insights on OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month safety and: What a 283-Participant Study Found OnabotulinumtoxinA effectively reduced the appearance of MMP and improved PROs, with effects lasting up to 6 months and a favorable safety profile. Aesthetic surgery journal • 2026-04-07 • Phase III Randomized Trial | N = 283 | 93/100 | PMID 41092464 ↗ |
| New Insights on Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term: What a 709-Participant Study Found Adjuvant NIVO for high-risk MIUC was associated with a higher cure fraction than PBO in the ITT and PD-L1 ≥1% populations. Clinical genitourinary cancer • 2025-06-15 • Phase III Randomized Trial | N = 709 | 93/100 | PMID 40204616 ↗ |
| Can This Approach Help? Inside the Latest Research on Characteristics and outcomes of patients with and without statin-associated Patients who reported SAMS, regardless of randomization to bempedoic acid or placebo, had higher rates of discontinuation, higher rates of skeletal muscle. Journal of clinical lipidology • 2025-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39939212 ↗ |
| Can This Approach Help? Inside the Latest Research on Whey Protein Supplementation on Muscle Damage, liver Stress, and Inflammatory The results highlight whey protein's potential as a nutritional aid to promote recovery and physiological adaptation, possibly mediated by antioxidant and anti-inflammatory mechanisms. European journal of sport science • 2026-11-15 • Randomized Controlled Trial | N = 30 | 88/100 | PMID 42929456 ↗ |
Muscle Cramps Patient Community & “People Like Me” Threads
Filter Muscle Cramps community threads and patient logs by age, biological sex, dosage, and treatment duration.